Please assess the completion status of the following clinical trial:

Trial Title: Preemptive Infiltration With Betamethasone and Ropivacaine for Postoperative Pain in Laminoplasty or Laminectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients scheduled for surgery under general anaesthesia for laminectomy or laminoplasty;~* American Society of Anaesthesiologists (ASA) classification of I or II;~* Age 18 to 64 years;~* Participates with an anticipated full recovery within 2 hours postoperatively.~Exclusion Criteria:~* Patient refusal;~* Participants who cannot use a patient-controlled analgesia (PCA) device and cannot understand the instructions of a Visual Analogue Score (VAS);~* Previous history of spinal surgery;~* Allergy to opioids, betamethasone or ropivacaine;~* Peri-incisional infection;~* History of stroke or a major neurological deficit;~* Trauma, deformity;~* Psychological problems;~* Extreme body mass index (BMI) (\< 15 or \> 35);~* History of excessive alcohol or drug abuse, chronic opioid use (more than 2 weeks), or use of drugs with confirmed or suspected sedative or analgesic effects;~* Patients using systemic steroids;~* Pregnant or breastfeeding;~* Preoperative Glasgow Coma Scale \< 15;~* Participants who have received radiation therapy or chemotherapy preoperatively, or with a high probability to require a postoperative radiation therapy or chemotherapy according to the preoperative imaging.~* Not able to give written informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- The Treatment Group (Type: EXPERIMENTAL): The local infiltration solution in the treatment group will consist of betamethasone and ropivacaine.
- The Control group (Type: ACTIVE_COMPARATOR): The local infiltration solution in the control group will consist of ropivacaine.

Based on this trial design, predict the completion outcome and termination type (if applicable).